Sutton Wealth Advisors Inc. Eagle Pharmaceuticals, Inc. Transaction History

Sutton Wealth Advisors Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 07, 2023	SELL	$26.42 - $47.12 $9,801 - $17,481	-371 Closed	0 $0
Q2 2022 Nov 07, 2023	SELL	$41.26 - $51.35 $330 - $410	-8 Reduced 2.11%	371 $16.5 Million
Q1 2022 Nov 07, 2023	BUY	$44.58 - $52.6 $267 - $315	6 Added 1.61%	379 $18.8 Million
Q4 2021 Nov 07, 2023	BUY	$45.82 - $56.9 $91 - $113	2 Added 0.54%	373 $19 Million
Q1 2019 Nov 06, 2023	BUY	$38.66 - $51.82 $14,342 - $19,225	371 New	371 $18.7 Million
Q4 2018 Nov 06, 2023	SELL	$36.72 - $67.73 $5,250 - $9,685	-143 Closed	0 $0
Q3 2018 Nov 06, 2023	BUY	$66.65 - $83.86 $9,530 - $11,991	143 New	143 $9.91 Million
Q1 2018 Nov 06, 2023	SELL	$52.16 - $66.86 $5,685 - $7,287	-109 Closed	0 $0
Q4 2017 Nov 06, 2023	BUY	$49.6 - $60.87 $1,091 - $1,339	22 Added 25.29%	109 $5.82 Million
Q3 2017 Nov 06, 2023	SELL	$46.62 - $60.36 $839 - $1,086	-18 Reduced 17.14%	87 $5.19 Million
Q3 2016 Nov 06, 2023	BUY	N/A	105	105 $7.35 Million

8.6M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Sutton Wealth Advisors Inc., based on Form 13F filings with the SEC.

Stay updated on Sutton Wealth Advisors Inc. with notifications on news.